FUJIY - Argenx inks manufacturing contract for efgartigimod with Fujifilm Diosynth

• Fujifilm Diosynth Biotechnologies on Thursday said it signed an agreement to manufacture argenx's ( NASDAQ: ARGX ) ( OTC:ARGNF ) monoclonal antibody efgartigimod to treat severe autoimmune disease.
• Fujifilm Diosynth, a unit of Japan's Fujifilm Holdings ( OTCPK:FUJIY ) ( OTCPK:FUJIF ), will provide drug substance manufacturing of efgartigimod at its large-scale biomanufacturing facility in Hillerød, Denmark.
• Terms of the agreement were not disclosed by the companies.
• Efgartigimod sold as Vyvgart, is approved in the U.S. and Europe to treat adults with generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder.
• "This collaboration underscores our employees’ commitment and ability to successfully onboard new programs and to provide a well-established and strong ecosystem to manufacture therapeutic antibodies for commercial use at a large-scale," said Fujifilm Diosynth COO Lars Petersen.

For further details see: